Maze Therapeutics, Inc. (MAZE)

NGM – Цена в реальном времени. Валюта: USD

25.96

+0.18 (0.70%)

Рынок открыт: May 13, 2026, 10:30 AM EDT

22.04.2026

Maze Therapeutics Announces $150 Million Registered Offering

SOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE) today announced the pricing of its underwritten registered offering of 5,540,000 shares of its common stock at a price of $23.50 per share. In addition, and in lieu of common stock, Maze is offering to certain investors pre-funded warrants to purchase up to an aggregate of 850,000 shares of common stock at a purchase price of $23.499 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds to Maze from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Maze, are expected to be $150 million. The offering is expected to close on or about April 23, 2026, subject to the satisfaction of customary closing conditions. All of the securities are being offered by Maze.

04.04.2026

Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors.

Chief Medical Officer Harold Bernstein sold 15,000 company shares for a transaction value of ~$442,000 at around $29.46 per share on April 1, 2026. This disposition represented 100% of Harold Bernstein's direct Common Stock holdings, reducing his direct ownership of Common Stock to zero.

27.03.2026

Maze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop

I am initiating coverage on Maze Therapeutics (MAZE) with a "Buy" rating following positive phase 2 HORIZON data for MZE829 in APOL1-mediated kidney disease. MZE829 achieved a 35.6% mean reduction in proteinuria, exceeding the ≥30% uACR threshold required for clinical relevance and potential regulatory advancement. Despite a 37% stock drop post-data, I view the market reaction as overblown given the program's success and planned pivotal trial initiation.

27.03.2026

After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Maze Therapeutics, Inc. (MAZE)

The heavy selling pressure might have exhausted for Maze Therapeutics, Inc. (MAZE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

26.03.2026

MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Maze Therapeutics, Inc. (NASDAQ: MAZE). The investigation focuses on Maze's executive officers and whether investor losses may be recovered under federal securities laws.

25.03.2026

Maze Insider Reports $736K Sale. Here's What Investors Should Know as Stock Plunges 33%

An executive at Maze Therapeutics reported selling 15,000 shares on March 20, 2026, yielding a transaction value of $736,000 at around $49.10 per share. The activity was executed directly, involved derivative mechanics (option exercise), and did not affect any indirect holdings.

25.03.2026

Maze Therapeutics Stock Falls Despite Strong Phase 2 Kidney Drug Data For MZE829

• Maze Therapeutics stock is among today's weakest performers. What's behind MAZE decline?

MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

25.03.2026

Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease

– At week 12, treatment with MZE829 resulted in a 35.6% mean uACR reduction in broad AMKD patients, 50% of the patients achieved a greater than 30% reduction in uACR, and treatment was well-tolerated – – The subgroup of AMKD patients with FSGS that were treated with MZE829 showed a 61.8% mean reduction in uACR – – Treatment of non-diabetic AMKD patients with MZE829 led to a clinically meaningful mean reduction in uACR from baseline of 48.6% – – Results provide first clinical proof-of-concept in genetically defined, broad AMKD population, including patients with moderate proteinuria and diabetes – – Maze plans to advance MZE829 to a pivotal program – – Maze to host investor conference call and webcast today at 8:00 am EDT – SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced positive topline data from the Phase 2 HORIZON trial of MZE829, an oral, small molecule, dual-mechanism APOL1 inhibitor, in patients with broad APOL1-mediated kidney disease (AMKD).

25.03.2026

Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host conference call today at 8:00 am EDT Two Phase 2 proof-of-concept clinical trials evaluating MZE782 in PKU and CKD expected to initiate in 2026 Industry leader Neil Kumar, Ph.D., Founder and CEO of BridgeBio, appointed to Maze Board of Directors Strong balance sheet with $360.0 million in cash, cash equivalents and marketable securities; expected cash runway into 2028 SOUTH SAN FRANCISCO, Calif.

Maze Therapeutics, Inc. (MAZE)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Maze Therapeutics, Inc. (MAZE)

Maze Therapeutics Announces $150 Million Registered Offering

Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors.

Maze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop

After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Maze Therapeutics, Inc. (MAZE)

MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Maze Insider Reports $736K Sale. Here's What Investors Should Know as Stock Plunges 33%

Maze Therapeutics Stock Falls Despite Strong Phase 2 Kidney Drug Data For MZE829

Видео

Пресс-релизы

Maze Therapeutics Announces $150 Million Registered Offering

MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease

Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Maze Therapeutics Announces $150 Million Registered Offering

Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors.

Maze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop

After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Maze Therapeutics, Inc. (MAZE)

MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Maze Insider Reports $736K Sale. Here's What Investors Should Know as Stock Plunges 33%

Maze Therapeutics Stock Falls Despite Strong Phase 2 Kidney Drug Data For MZE829

Видео

Пресс-релизы

Maze Therapeutics Announces $150 Million Registered Offering

MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease

Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Search stocks

Maze Therapeutics, Inc. (MAZE)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Maze Therapeutics, Inc. (MAZE)

Maze Therapeutics Announces $150 Million Registered Offering

Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors.

Maze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop

After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Maze Therapeutics, Inc. (MAZE)

MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Maze Insider Reports $736K Sale. Here's What Investors Should Know as Stock Plunges 33%

Maze Therapeutics Stock Falls Despite Strong Phase 2 Kidney Drug Data For MZE829

Видео

Пресс-релизы

Maze Therapeutics Announces $150 Million Registered Offering

MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease

Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Maze Therapeutics Announces $150 Million Registered Offering

Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors.

Maze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop

After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Maze Therapeutics, Inc. (MAZE)

MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Maze Insider Reports $736K Sale. Here's What Investors Should Know as Stock Plunges 33%

Maze Therapeutics Stock Falls Despite Strong Phase 2 Kidney Drug Data For MZE829

Видео

Пресс-релизы

Maze Therapeutics Announces $150 Million Registered Offering

MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease

Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights